•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Tilray Brands shares have fallen more than 95% over the past five years, a decline that has led some investors to view the stock with skepticism. Others see it as a low-priced opportunity that could rebound and generate strong returns. The question is whether Tilray is a classic value trap—or simply a beaten-down value stock.
At first glance, Tilray does not appear to meet the usual value-trap profile of a low valuation. Even after its steep drop, the marijuana stock trades at 57.5 times trailing 12-month earnings.
However, another metric points in a different direction: Tilray’s price-to-book ratio is 0.54. A low price-to-book multiple can suggest a stock is undervalued, but in Tilray’s case, the underlying balance-sheet composition matters.
Book value is calculated by subtracting total liabilities from total assets. Tilray’s book value is about $1.52 billion, but roughly half of that figure—approximately $752 million—is goodwill. The company also reports about $23 million in intangible assets.
Tilray has written off significant amounts of goodwill in the past, and there is no guarantee it will not do so again. If additional goodwill is impaired, the price-to-book valuation could look far less attractive.
Supporters of the “value stock” view argue that Tilray’s challenges are driven more by broader market conditions than by company-specific mistakes. The supply of cannabis has exceeded demand, pressuring prices. If that imbalance improves, Tilray could benefit.
The company also highlights diversification across cannabis and adjacent categories. Tilray ranks No. 1 in the Canadian adult-use cannabis market. In the U.S., it is the fourth-largest craft brewer. Its wellness products hold a 60% market share in North America’s branded hemp foods and snacks category, and Tilray is a leader in global medical cannabis, selling products in more than 20 countries.
Value traps often struggle to control costs, but Tilray has reported cost savings of around $200 million in recent years.
The company’s balance sheet has also improved. A year ago, Tilray had a net debt position of $36.6 million. As of Feb. 28, 2026, it reported a net cash position of $3.5 million, supported by cash, restricted cash, and marketable securities of $264.8 million.
Tilray may also benefit from a regulatory shift in the U.S. The process of reclassifying marijuana from Schedule I to Schedule III would lift IRS Section 280E restrictions. Those restrictions limit cannabis companies’ ability to deduct business expenses that most other companies can deduct. If rescheduling is finalized, Tilray’s bottom line could improve.
Overall, the evidence points to a middle ground. Tilray could deliver strong gains if its diversification strategy works and industry headwinds ease. At the same time, the stock could remain under pressure if cannabis market conditions do not improve.
The article’s conclusion is that Tilray is best viewed as a relatively risky turnaround play rather than a textbook value trap or a clear-cut bargain.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
